- Report
- May 2024
- 200 Pages
Global
From €3933EUR$4,150USD£3,319GBP
- Report
- May 2024
- 200 Pages
Global
From €3933EUR$4,150USD£3,319GBP
- Report
- May 2024
- 200 Pages
Global
From €3933EUR$4,150USD£3,319GBP
- Report
- August 2024
- 62 Pages
Global
From €943EUR$995USD£796GBP
- Report
- October 2024
- 200 Pages
Global
From €4690EUR$4,949USD£3,958GBP
- Report
- July 2024
- 171 Pages
Global
From €4264EUR$4,500USD£3,599GBP
- Report
- December 2024
- 150 Pages
Global
From €3743EUR$3,950USD£3,159GBP
- Report
- July 2024
- 153 Pages
Global
From €4027EUR$4,250USD£3,399GBP
- Report
- August 2024
- 200 Pages
Global
From €4690EUR$4,949USD£3,958GBP
- Report
- July 2024
- 200 Pages
Global
From €4690EUR$4,949USD£3,958GBP
- Report
- August 2024
- 200 Pages
Global
From €4690EUR$4,949USD£3,958GBP
- Report
- July 2024
- 200 Pages
Global
From €4690EUR$4,949USD£3,958GBP
- Report
- April 2024
- 140 Pages
Global
From €4690EUR$4,949USD£3,958GBP
- Report
- January 2025
- 247 Pages
Global
From €4733EUR$4,995USD£3,995GBP
- Report
- March 2025
- 136 Pages
Global
From €4733EUR$4,995USD£3,995GBP
- Report
- December 2024
- 341 Pages
Global
From €3411EUR$3,600USD£2,879GBP
- Report
- January 2025
- 50 Pages
Global
From €2368EUR$2,499USD£1,999GBP
- Report
- January 2025
- 53 Pages
Global
From €2368EUR$2,499USD£1,999GBP
- Report
- March 2025
- 84 Pages
Global
From €5307EUR$5,600USD£4,478GBP
- Report
- February 2025
- 341 Pages
Global
From €3838EUR$4,050USD£3,239GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more